Mécanismes des effets diabétogènes des médicaments antipsychotiques

Obesity, metabolic syndrome, and diabetes, are a major source of morbidity and mortality in schizophrenic patients receiving long-term treatment with antipsychotics, and contribute to reduce their life expectancy. More specifically, the diabetogenic effects of antipsychotics involve both weight-dependent and -independent effects. The obesiogenic actions are related to the orexigenic properties of these drugs, which interfere with signalling pathways implicated in the regulation of food intake. However, independently of body weight induction, antipsychotics can also alter insulin secretion and insulin sensitivity. A better knowledge of these mechanisms is a prerequisite for the future development of compounds with less deleterious metabolic adverse effects.